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Abstract
Background: The COPD Assessment Test (CAT™) is a new short health status measure for routine use. New
questionnaires require reference points so that users can understand the scores; descriptive scenarios are one way
of doing this. A novel method of creating scenarios is described.
Methods: A Bland and Altman plot showed a consistent relationship between CAT scores and scores obtained
with the St George’s Respiratory Questionnaire for COPD (SGRQ-C) permitting a direct mapping process between
CAT and SGRQ items. The severity associated with each CAT item was calculated using a probabilistic model and
expressed in logits (log odds of a patient of given severity affirming that item 50% of the time). Severity estimates
for SGRQ-C items in logits were also available, allowing direct comparisons with CAT items. CAT scores were
categorised into Low, Medium, High and Very High Impact. SGRQ items of corresponding severity were used to
create scenarios associated with each category.
Results: Each CAT category was associated with a scenario comprising 12 to 16 SGRQ-C items. A severity ‘ladder’
associating CAT scores with exemplar health status effects was also created. Items associated with ‘Low’ and
‘Medium’ Impact appeared to be subjectively quite severe in terms of their effect on daily life.
Conclusions: These scenarios provide users of the CAT with a good sense of the health impact associated with
different scores. More generally they provide a surprising insight into the severity of the effects of COPD, even in
patients with apparently mild-moderate health status impact.
Background
Understanding a chronic obstructive pulmonary disease
(COPD) patient’s health status is an integral part of
overall patient management. International guidelines on
the management of COPD recommend that both lung
function and health status are monitored regularly to
guide any changes in treatment [1], and both the Eur-
opean Respiratory Society and the American Thoracic
Society recommend that health status should be
assessed as an outcome in clinical trials of new and
existing pharmacological therapies for treatment of
COPD [2]. A number of different questionnaires are
available that assess health status in COPD, these
include the Chronic Respiratory Questionnaire (CRQ)
[3], the Clinical COPD Questionnaire (CCQ) [4], the St.
Georges Respiratory Questionnaire (SGRQ) [5] and a
revised form of the SGRQ, SGRQ-C, which retains the
accuracy and responsiveness of the SGRQ but which
features fewer questions; scores obtained with the
SGRQ and SGRQ-C are directly comparable [6].
All health status questionnaires require reference
points so that physicians can attach meaning to their
scores. One approach is to calculate a minimum clini-
cally important difference (MCID). This allows users of
the questionnaire to distinguish clinically relevant differ-
ences within patients, for example in an interventional
trial, or in the same patient over time, for example
before and after pulmonary rehabilitation. However, the
MCID only provides an estimate of the minimum
worthwhile difference and does not describe in what
nature the health status has changed [7]. Another
approach is to relate scores to clinical scenarios. This
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SGRQ [8], where the scenarios are based on responses
to individual questions. For example, a scenario describ-
ing a patient who; no longer takes a long time to wash
or dress, can now walk up stairs without stopping and go
out for entertainment relates to a pattern of change in
the patients health status correspondent to a 4-unit
improvement. Despite these useful descriptive character-
istics, within the field of pulmonary medicine there has
been no attempt to create scenarios that can provide
clinicians with descriptions that cover the entire range
of a health status scale.
We have recently described the development of a new
simple health status questionnaire, the COPD Assess-
ment Test (CAT™) [9,10], which correlates very well
with the SGRQ-C in stable COPD patients (r = 0.80) and
in patients experiencing an exacerbation (r = 0.78). This
paper describes the development of descriptive scenarios
for the CAT based upon the content of the SGRQ-C.
’Mapping’ the contents of SGRQ-C to the CAT was
possible as the CAT was developed using Rasch metho-
dology while development of the SGRQ-C involved ret-
rospective Rasch analysiso ft h eo r i g i n a lS G R Qt o
identify items that could be removed. Consequently it
has been possible to convert both questionnaires scores
to a common unit of measurement that then allows
direct comparison between CAT scores and SGRQ item
severity scores, and subsequent mapping of SGRQ-C
scenarios to the full spectrum of CAT scores.
Methods
Comparison of CAT and SGRQ scores
The correlation between SGRQ and CAT scores in
stable patients is good (r = 0.80) [9], however a better
method of assessing the agreement of two instruments
designed to measure the same thing is a technique
known most commonly as the Bland and Altman plot
[11]. This tests whether the two instruments behave in
the same way across the entire scaling range of the
instruments, by plotting the difference between mea-
surements made by the two instruments in the same
individual against the mean of the two measurements.
The differences should be small across the scaling range
and have no, or only a very small, correlation with the
means. The CAT scale ranges from 0 to 40 while the
SGRQ scale ranges from 0 to 100, therefore in order to
create a Bland and Altman plot, it was necessary to
multiply the CAT score by 2.5 to make the scaling
r a n g ed i r e c t l yc o m p a r a b l ew i t ht h a to ft h eS G R Q .T h i s
CAT score was called the ‘adjCAT’.
Rasch analysis
Rasch methodology is based upon testing the perfor-
mance of the Guttman scaling properties of a
questionnaire’s constituent items [12-14]. The key prop-
erty of this type of scale is the assumption that, for an
item of given severity, a patient will have a high prob-
ability of responding positively to items that indicate les-
ser severity than the item in question and a lower
probability of responding positively to items that reflect
greater severity, when a positive response denotes the
presence rather than the absence of an impairment or
disability. Rasch modelling was used in the development
of CAT, as described elsewhere [9]. Using this approach,
severity is calculated as the log odds (logit) of a patient
affirming that item 50% of the time. The average sever-
ity of the items is conventionally fixed at zero logit,
therefore a mild score has a negative logit and a severe
score has a positive logit.
Scoring the CAT
The item reduction stage of CAT development used
Rasch analysis to determine the eight items that formed
the final questionnaire [9]. This model confirmed that
the CAT met the requirements for a unidimensional
scale. As a result, a reliable score of overall health status
could be calculated using the simple sum of the patient’s
responses to the items. In a questionnaire developed
using Rasch modelling, the relationship between the
questionnaire’s score, calculated as the simple sum, and
severity scored in logits forms a mathematically defined
relationship. A conversion table allows CAT scores to
be converted to logits or vice versa. An abbreviated ver-
sion is shown in Table 1 and the full version is included
in Additional File 1: Appendix 1.
Scoring the SGRQ
Scores for the SGRQ are calculated by applying empiri-
cally derived weights to the patients’ responses to each
item. This is an entirely different methodology from that
used for scoring the CAT and meant that a simple direct
mapping exercise to relate CAT scores to SGRQ scores
was not possible. However, a recent exercise to refine the
Table 1 Abbreviated conversion table from CAT score to
logits
CAT score CAT logits
0 -4.31
5 -1.90
10 -1.03
15 -0.43
20 0.07
25 0.55
30 1.07
35 1.82
40 4.01
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[6]. This process also provided estimates of the severity of
each item calculated as logits, which made it possible to
compare CAT scores and SGRQ items using the same
metric. Most of the items in the SGRQ are dichotomous,
so we used the logit for that item. About 15% of the items
have multiple response categories and in these cases we
used the logit for each category of response.
Mapping CAT scores to SGRQ items
CAT scores had already been categorised into severity
bands, as described in the CAT users guide (http://
www.catestonline.org): Low Impact (CAT score 1 to 10),
Medium Impact (11 to 20), High Impact (21 to 30),
Very High Impact (31 to 40) (Figure 1). This categorisa-
tion took place prior to the analysis presented here and
was not based on any knowledge of mapped SGRQ
items. Scenarios were created for each category by map-
ping them to SGRQ-C items of corresponding severity
using CAT categories and SGRQ-C item severity
expressed in logits (Figure 2).
Patients
Patients were recruited from sites in Belgium, France,
Germany, The Netherlands, Spain, UK, and USA. Full
details of patient recruitment and questionnaire admin-
istration are available elsewhere [9]. The study was con-
ducted in compliance with the Declaration of Helsinki
with ethics approval provided by local ethics commit-
tees. All patients provided written informed consent
prior to study procedures.
Results
CAT categories within a COPD population
Full details of these patients have been published else-
where [9], in brief their mean age was 66 years, 32%
were female and their mean FEV1 was 58% predicted. In
Figure 1, the CAT severity categories are superimposed
upon a cumulative frequency distribution of CAT scores
in 1503 patients recruited from Belgium, France, Ger-
many, The Netherlands, Spain, UK, and USA. The pro-
portion of scores was 18% Low Impact, 43% Medium
Impact, 28% High Impact, and 11% Very High Impact.
Correlation with SGRQ
SGRQ and CAT scores were obtained in the same
patients. The Bland and Altman plot in Figure 3 showed
av e r ys t a b l er e l a t i o n s h i pacross the scaling range,
although there was a very small positive correlation (r =
0.16, p = 0.005). At the mild end of the CAT scale the
score slightly over-estimated severity by a small amount
Figure 1 Cumulative frequency distribution of CAT scores.
Figure 2 Mapping CAT scores to SGRQ items.S e et e x tf o rf u l l
explanation.
Figure 3 Bland and Altman plot of SGRQ and adjCAT scores.
CAT scores were converted to 0 to 100% (adjCAT) to match SGRQ
scores. The X axis is the mean of the SGRQ and adjCAT scores; the y
axis is SGRQ-adjCAT score. The correlation for a linear regression
was r = 0.16, p = 0.005.
Jones et al. BMC Pulmonary Medicine 2011, 11:42
http://www.biomedcentral.com/1471-2466/11/42
Page 3 of 7(SGRQ = 0, adjCAT = 5, equivalent to 2 CAT units)
and at the severe end it slightly under-estimated severity
(SGRQ = 100, adjCAT = 92.5, equivalent to 37 CAT
units). This level of agreement was sufficient to permit
direct mapping between SGRQ and CAT for the pur-
pose of creating these scenarios.
The Bland and Altman plot also shows the limits of
agreement between CAT and SGRQ; 31% of the score
differences are less than 5 points (i.e. difference of ≤5%)
and 60% are less than 10 points (difference of ≤10%),
and 90% are less than 20 points (difference of ≤20%).
These numbers show substantial agreement between the
CAT and SGRQ.
Creation of CAT scenarios
The SGRQ-C items associated with each of the CAT
categories are listed in Table 2. A representative selec-
tion of these items was used to create the brief scenarios
described in the CAT user guide [http://www.cateston-
line.org].
COPD ladder of severity
An alternative method of showing the relationship
between CAT score and SGRQ-C scenarios is shown in
Table 3. Representative items for each 5-point step
along the CAT are listed in ascending order of severity.
This is termed a ‘ladder of severity’ because at each
level, it is likely that the patient will also have experi-
enced the development of many of the health affects
associated with the milder steps up to their current
severity.
Discussion
This analysis has used an objective scientific method to
create clinical scenarios that are associated with differ-
ent scores obtained with a new measure of impaired
health status for COPD. A number of factors made this
possible: 1. Rasch-imputed mapping has been used suc-
cessfully in other diseases to map measures between two
instruments [15], and develop scenarios corresponding
to outcomes within an instrument [16]; 2. CAT scores
and SGRQ-C scores correlate well across the entire scal-
ing range from very mild to very severe; 3. The CAT
scores and SGRQ-C items could be expressed in the
same units of measurement; 4. The SGRQ is made up
of sufficient items (some of which have multiple
response options, each with its own calculated logit
value) to permit relatively rich descriptions, so each
CAT category was associated with 12 or more SGRQ-C
items; 5. Rasch models are thought to be sample inde-
pendent [17], thereby permitting comparisons between
different groups of patients.
This approach enabled us to provide scenarios that
describe patients exhibiting CAT scores ranging from
the very mild to the very severe. For example, patients
who become breathless while walking up hills fall into
the Low Impact CAT category, while those who become
breathless while walking around the home fall into the
Very High Impact category. These scenarios allow for a
more rounded understanding of the effects of COPD
associated with different CAT scores and for a more
ready appreciation of what the scores mean for the
patient in terms of the effect of COPD on their lives.
The data used to map SGRQ-C items to CAT severities
were derived from multiple countries and, during the
CAT’s development, items that performed differently in
different countries were excluded. For these reasons, we
believe that large regional variation in the scenarios is
unlikely and that they are applicable wherever a valid
translation of CAT is available (current list available at
http://www.catestonline.org).
There are, however, some weaknesses with the
approach used here. Ideally, the Rasch analysis would
have been performed on the same patient population as
that used for the CAT analysis, but this was not possible
for resource reasons. However, we have shown pre-
viously that within a study population repeat estimates
of item severity calculated using Rasch analyses were
very stable over time [13]. The items in the SGRQ-C
don’t provide a fully comprehensive description of every
effect that COPD can have on a person, but there are
common effects that shouldb ee x p e r i e n c e db ym o s t
patients. Some of the items do not seem intuitively to
be of the ‘right’ severity, for example bringing up
phlegm only with chest infections is associated with a
similar degree of severity as having to stop when walk-
ing up stairs, however these severity estimates were cal-
culated using data from approximately 900 COPD
patients [6] so they should be reliable. Finally, as the
cut-point for categories for CAT severity were chosen
ad hoc and on a purely descriptive basis rather than on
empirical clinical definition, there is the possibility that
where items mapped from the SGRQ-C fell close to the
border between two severity categories they may have
been mis-assigned. It is beyond the scope of this work
to validate the CAT severity categories, and it is
acknowledged that future work may be needed to pro-
spectively both test the validity of the CAT severity
categories (and SGRQ-C mapping) in a cohort of
patients in whom data is collected using both SGRQ-C
and the CAT, and to relate the CAT severity categories
to needs of care.
An alternative approach to conveying the impact of
COPD, as reflected in CAT scores, is to present a usable
number of selected SGRQ items in an ascending hierar-
chy of severity or ladder. When using such a ladder it is
important to remember that higher scores are likely to
be associated with many of the milder items; a patient
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also likely to do housework slowly and be unable to do
one or two things that they would like to do. By the
same token, they are less likely to be breathless when
walking around the home or have problems bathing.
This COPD severity ladder is presented as an alternative
approach to scenarios for providing clinicians with a
picture of the life and health of a COPD patient with
any given CAT score. It is important to note that it
should not be used as a scale and CAT scores should
not be attributed to the patient’s response to selected
items from this ladder - its purpose is purely illustrative.
One important contribution of this work is to focus
attention on the true impact of COPD on a patient’s
life. In this respect, the very general adjectives used to
describe the severity of the impact of the disease on the
Table 2 SGRQ-C items grouped by corresponding CAT severity category
Low Impact
(CAT 1-10)
Medium Impact
(CAT 11-20)
High Impact
(CAT 21-30)
Very High Impact
(CAT 31-40)
Breathless several days a
week
(-3.86)
Housework takes long or
stop for rests
(-0.91)
Chest causes lot of problems or most
important problem
(0.15)
Cough causes tiredness
(1.13)
Breathless walking up hills
(-3.72)
Breathless most days a
week
(-0.80)
3 or more attacks of chest trouble in
last year
(0.20)
Takes a long time to get washed
or dressed
(1.24)
Difficult to carry heavy loads,
etc (-3.16)
Bring up phlegm several days
a week
(-0.77)
Get afraid/panic when can’t get breath
(0.21)
Breathless walking around home
(1.47)
Have to stop/slow down if
hurry/walk fast
(-2.98)
Wheezing attacks only with
chest infections
(-0.68)
Breathless walking on level ground
outside the house
(0.32)
Chest trouble is a nuisance to family,
friends (1.49)
Chest condition causes a few
problems
(-2.91)
Cough several days a week
(-0.64)
Wheezing attacks several days a week
(0.36)
Cannot take bath/shower or takes
long time (1.55)
Difficult to walk up hill, light
gardening, etc
(-2.64)
Wheezing attacks a few days
a month
(-0.35)
Cough and/or breathing embarrassing in
public
(0.47)
Cannot go out for entertainment
(1.87)
Most days are good in average
week
(-2.63)
1-2 attack of chest trouble in
last year
(-0.30)
Cough and/or breathing disturbs sleep
(0.49)
Coughs hurts (2.11)
Stops 1 or 2 things
(-2.15)
Bring up phlegm most days a
week
(-0.21)
Feel not in control of chest problem
(0.49)
Cannot do housework
(2.20)
Breathless walking up a flight of
stairs
(-2.15)
A few good days in an
average week
(-0.19)
Wheezing attacks most days a week
(0.58)
Have become frail or invalid because
of chest (2.42)
Cough only with chest
infections
(-2.06)
Cough most days a week
(-0.09)
Stops patient doing most things they
want to do (0.60)
Cannot go out of house for shopping
(2.69)
Walk slower than others or stop
for rests
(-1.52)
Breathless when bending
over
(-0.07)
Breathless getting washed/dressed (0.62) Stops patient doing everything they
want to do (3.11)
Breathless only with chest
infections
(-1.52)
Wheeze worse in morning
(-0.02)
No good days in average week (0.63) Cannot move far from bed or chair
(3.40)
Get exhausted easily
(-1.47)
Breathless when talking
(0.81)
Walk slowly or stop walking one
flight of stairs
(-1.14)
Exercise felt not to be safe
(0.92)
Bring up phlegm only with
chest infections
(-1.07)
Everything seems too much of an effort
(0.92)
Usually cannot play sports or
games
(-1.05)
Figure in bold brackets is the SGRQ-C item’s severity expressed in logits; low score (negative) = mild, high score (positive) = severe
Jones et al. BMC Pulmonary Medicine 2011, 11:42
http://www.biomedcentral.com/1471-2466/11/42
Page 5 of 7patient may be doing a disservice to the patient. A
‘Medium Impact’ CAT score looks anything but med-
ium when described as a scenario, most healthy people
are likely to judge that getting exhausted easily and
needing to take a long time to do housework constitutes
q u i t es e v e r ei m p a c to nh e a l t h .I fu s eo ft h eC A Ta n d
these scenarios produces a re-evaluation of what consti-
tutes ‘mild or moderate COPD’, then patients can only
benefit.
Conclusion
In conclusion, this work has shown that it is possible to
relate CAT scores to scenarios descriptive of impaired
health status in COPD. The CAT is a concise instru-
ment for use in everyday clinical practice; the scenarios
described here allow for a more complete understanding
of what its scores reflect in terms of the effect of the
disease on the patient’s health. It is our hope that a
more complete understanding of a COPD patient’s
health status may help clinicians optimise their
management.
Additional material
Additional file 1: Appendix 1: Conversion table from CAT score to
logits.
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